SCHEMBL6802997

SCHEMBL6802997

O=C(Nc1cncn(C(C(=O)O)c2ccc(Cl)cc2)c1=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
MAPT P10636 4/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
TP53 P04637 2/20 0.42
MDM4 O15151 1/20 0.42
MDM2 Q00987 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 1/20 0.42
KCNMA1 Q12791 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805321 0.92 IDO1 (0.47) RAB9AMAPTNPC1SMN1; SMN2CYP1A2
SCHEMBL6803439 0.89 ALDH1A1 (0.47) RAB9AMAPTNPC1SMN1; SMN2IDO1
SCHEMBL6805808 0.89 SMN1; SMN2 (0.47) RAB9AMAPTNPC1SMN1; SMN2IDO1
SCHEMBL6805622 0.89 IDO1 (0.43) MAPTSMN1; SMN2CYP2C19IDO1TDO2
SCHEMBL6799314 0.86 RAB9A (0.49) RAB9AMAPTNPC1SMN1; SMN2TP53
SCHEMBL6803978 0.85 KMT2A (0.47) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL6803679 0.83 RAB9A (0.50) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6805953 0.82 IDO1 (0.41) RAB9AMAPTNPC1SMN1; SMN2IDO1
SCHEMBL6810352 0.81 NPC1 (0.47) RAB9AMAPTNPC1SMN1; SMN2CYP1A2
SCHEMBL6803731 0.80 IDO1 (0.41) RAB9AMAPTNPC1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS RAB9A 2244/4885MAPT 3790/4885NPC1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.